Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Halts Development Of Actos Combination Product

This article was originally published in The Pink Sheet Daily

Executive Summary

Japanese drug maker will focus on other projects in diabetes after ending fixed-dose combination of Actos with its angiotensin receptor blocker azilsartan.

You may also be interested in...



Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data

A cholesterol drug Takeda had planned to file in the first quarter of 2008 has been delayed after elevated transaminase levels were seen in some patients taking a higher dose of the product in clinical trials, the Japanese firm announced Oct. 29. FDA has requested additional clinical trial data on TAK-475 (lapaquistat), a squalene synthase inhibitor

Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data

Takeda had planned to file TAK-475 in the first quarter of 2008 but is now awaiting additional study data.

Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data

Takeda had planned to file TAK-475 in the first quarter of 2008 but is now awaiting additional study data.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066158

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel